Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01771107 · OUTCOME

Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma · Source last updated 2025-08-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
95% Confidence Interval
Time frame
Baseline up to 2 years

What was measured

Log-rank analysis will be used to investigate the prognostic value of FDG-PET scans at baseline, after 2 courses and post-therapy in patients with HIV and HL with respect to progression free survival.

Analysis population: PET-CT positive status was used within each arm.

Groups in this outcome

Phase I - Brentuximab 1.2 mg/kg

Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV

Phase II - Brentuximab 1.2 m/kg

Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I - Brentuximab 1.2 mg/kg6
Phase II - Brentuximab 1.2 m/kg35

Reported measurements

PET-CT positive

Analysis denominator · Participants

GroupSource count
Phase I - Brentuximab 1.2 mg/kg6
Phase II - Brentuximab 1.2 m/kg33
Values in proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Phase I - Brentuximab 1.2 mg/kg0.876Not reported0.7010.951Not reported
Phase II - Brentuximab 1.2 m/kg0.876Not reported0.7010.951Not reported
PET-CT negative

Analysis denominator · Participants

GroupSource count
Phase I - Brentuximab 1.2 mg/kg0
Phase II - Brentuximab 1.2 m/kg2
Values in proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Phase II - Brentuximab 1.2 m/kg0Not reported00Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.701
        upper Limit
        0.951
        value
        0.876
      2. group Id
        OG001
        lower Limit
        0.701
        upper Limit
        0.951
        value
        0.876
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        33
      units
      Participants
    title
    PET-CT positive
  2. categories
    1. measurements
      1. group Id
        OG001
        lower Limit
        0
        upper Limit
        0
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
      units
      Participants
    title
    PET-CT negative
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      35
    units
    Participants
description
Log-rank analysis will be used to investigate the prognostic value of FDG-PET scans at baseline, after 2 courses and post-therapy in patients with HIV and HL with respect to progression free survival.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
    id
    OG000
    title
    Phase I - Brentuximab 1.2 mg/kg
  2. description
    Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV
    id
    OG001
    title
    Phase II - Brentuximab 1.2 m/kg
param Type
NUMBER
population Description
PET-CT positive status was used within each arm.
reporting Status
POSTED
time Frame
Baseline up to 2 years
title
Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival
type
SECONDARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice